Ibudilast in the Treatment of Patients With Chronic Migraine.

Exclusion Criteria

• •Change in type or dose of migraine prophylactic medication in last 3 months
• •Medication overuse headache as diagnosed according to the ICHD-IIR
• •Post-traumatic headache as diagnosed according to the ICHD-II
• •Other dominant chronic pain condition
• •Known active inflammatory diseases such as rheumatoid arthritis
• •History of recent cerebrovascular disorder
• •Unable to provide written informed consent
• •Unable to read and write in English
• •Severe psychological/psychiatric disorders
• •Recent history of significant trauma, as determined by the Principal Investigator including major surgery within the previous 2 months or major surgery planned during the treatment period
• •Recent history of drug or alcohol abuse
• •Any clinically significant findings on screening blood sample results
• •Current malignancy
• •Known hypersensitivity to ibudilast or excipients in Ketas® formulation
• •Renal or hepatic impairment, defined as baseline GFR (as calculated by the Cockcroft-Gault equation) of \<60 mL/min, LFTs (excluding bilirubin) \> 3 times the upper limit of normal or bilirubin \> 2 times the upper limit of normal
• •For females of childbearing potential:
• •* Pregnancy
• •* Lack of adequate contraception (abstinence, double barrier method, intrauterine device, surgical sterilization (self or partner), hormonal contraceptive methods (oral, injected, or implanted)
• •* Breastfeeding